Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotheraphy
    • Applied and Environmental Mircobiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotheraphy
    • Applied and Environmental Mircobiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Molecular Identification of Extended-Spectrum-β-Lactamase Genes from Enterobacteriaceae Isolated from Healthy Human Carriers in Switzerland

Nadine Geser, Roger Stephan, Bozena M. Korczak, Lothar Beutin, Herbert Hächler
Nadine Geser
Institute for Food Safety and Hygiene, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Stephan
Institute for Food Safety and Hygiene, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bozena M. Korczak
Institute of Veterinary Bacteriology, Vetsuisse Faculty University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lothar Beutin
Federal Institute for Risk Assessment, National Reference Laboratory for Escherichia coli, D-14195 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herbert Hächler
Institute for Food Safety and Hygiene, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.05539-11
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In this study, fecal samples from 586 healthy humans were investigated to determine the occurrence of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae in Swiss people. A total of 5.8% of the human fecal samples yielded ESBL producers, and all of the 34 isolated strains were Escherichia coli. PCR analysis revealed that 14 strains produced CTX-M-15, 10 produced CTX-M-1, 7 strains produced CTX-M-14, and 2 strains produced CTX-M-2 ESBLs. One strain produced SHV-12 ESBL. Of the 34 isolates, 15 produced additional TEM-1 broad-spectrum β-lactamases. By serotyping, a high degree of diversity among the strains was found.

TEXT

Antimicrobial resistance in bacteria has emerged as a problem in both human and veterinary medicine. One of the currently most important resistance mechanisms in Enterobacteriaceae, which reduces the efficacy even of modern expanded-spectrum cephalosporins (except cephamycins and carbapenems) and monobactams, is based on plasmid-mediated production of extended-spectrum β-lactamases (ESBL). Until now, more than 600 ESBL variants are known. Among them, the over 100 CTX-M enzymes so far reported may be grouped into five main subgroups (3). As a matter of growing concern, resistance caused by ESBLs is often associated with resistance to other classes of antibiotics like fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole (5, 15). In the past few years, there has been an increase in the detection of ESBL-producing strains in the general community (26). Three studies have been published about ESBL prevalence in healthy humans, establishing prevalences between 6 and 7% (25, 26, 36). More recently, several alarming studies have reported the dissemination of ESBL-producing Enterobacteriaceae to (i) healthy food-producing animals in several countries in Europe and Asia (7, 8, 16, 27, 35) and (ii) food products like meat, fish, and raw milk (17, 19, 20). Moreover, ESBL producers are also reported increasingly among infection-associated enterobacterial isolates in France (9, 23), Italy (4), the Czech Republic (21), and Austria (10). These studies were the reason to look for ESBL producers also in Switzerland, a country—located between the mentioned ones—with a tight policy of antibiotic prescription and a low level of multidrug resistance in bacteria (12). The aim of the present study was to screen for the occurrence of ESBL-producing Enterobacteriaceae in healthy human carriers in Switzerland and to further characterize isolated strains and ESBLs.

In an ongoing study of routine stool samples from staff members of meat-processing companies, fecal samples were collected from September to November 2010 from 586 healthy humans. The native samples were transported in sterile tubes without transport medium and were processed within 24 h of collection. All samples were collected in urban areas, and each person was tested only once. The population consisted of adults without diarrhea aged between 20 and 60 years, a quarter being female.

One loopful of each sample was enriched for 24 h at 37°C in 10 ml of EE broth (BD, Franklin Lakes, NJ), streaked onto Brilliance ESBL agar (Oxoid, Hampshire, United Kingdom), and incubated at 37°C for 24 h under aerobic conditions. Colonies of different morphology were selected and subcultured onto triple sugar iron (TSI) agar (BD, Franklin Lakes, NJ) at 37°C for 24 h. Nonfermenters were discarded, and oxidase-negative colonies were subjected to identification by API ID 32 E (bioMérieux, Marcy l'Etoile, France). Serotyping was performed according to standard methods (32).

All isolated strains were subjected to susceptibility testing against 15 antimicrobial agents (Table 1) by the disk diffusion method according to CLSI protocols and evaluated according to CLSI criteria (6). Presumptive ESBL producers were confirmed on Mueller-Hinton agar plates using Etest-ESBL strips containing cefotaxime, cefepime, or ceftazidime, each alone and in combination with clavulanic acid (bioMérieux, Marcy l'Etoile, France).

View this table:
  • View inline
  • View popup
Table 1

Identification and further characterization of the 34 ESBL producers isolated from fecal samples of 586 healthy human carriers in Switzerlanda

Bacterial strains confirmed as producing ESBLs were further analyzed by PCR and by sequencing the whole open reading frames (ORF) of bla genes. DNA was extracted by a standard heat lysis protocol. Thereafter, five specific published primer sets (custom synthesized by Microsynth, Balgach, Switzerland) and PCR protocols (13, 30, 33, 38) were used to search for β-lactamase-encoding genes belonging to blaTEM, blaSHV, and three blaCTX-M subfamilies. In order to ensure coverage of all entire bla ORFs, the primer sets were supplemented with the following newly designed primers from up- and downstream blaCTX-M flanking regions: 5′AAACACACGTGGAATTTAGGG3′, 5′CCGTCGGTGACGATTTTAGCC3′, 5′CCGATGACTATGCGCACTGGG3′, 5′TTTTGCCGTACCTGCGTACCC3′, 5′CCGTGGGTTACGATTTTCGCC3′, 5′TTGGTCCAGAAAAAAGAGCGG3′, 5′TGATGTAACACGGATTGACCG3′ 5′AAACCAGTTACAGCCCTTCGG3′, and 5′TGGAGCCACGGTTGATGAGGG3′ (this study). The resulting amplicons were purified using the PCR purification kit (Qiagen, Courtaboeuf, France) according to the manufacturer's recommendations. Custom sequencing was performed by Microsynth (Balgach, Switzerland), and the nucleotide and protein sequences were analyzed with Codon Code Aligner v. 3.7.1.1. For database searches the BLASTN program of NCBI (http://www.ncbi.nlm.nih.gov/blast/) was used.

ESBL-producing strains were isolated from 34 healthy human carriers (5.8%). This is an average carriage rate compared to an estimated <3%, 5.5%, an estimated >10%, and 13.2% in Sweden, Spain, India, and Saudi Arabia, respectively (34). All 34 ESBL producers showed a synergy effect with at least one of the three Etest-ESBL strips, and they yielded factors >8 when ratios of MIC (cephalosporin)/MIC (cephalosporin + clavulanic acid) were calculated. Identification of all 34 isolates yielded Escherichia coli (Table 1). The β-lactamase genes of all ESBL-producing isolates were further characterized by PCR and sequencing (Table 1). One bla gene coded for a SHV ESBL (SHV-12), and 33 genes coded for CTX-M ESBLs. Of the blaCTX-M genes, 24 (70.6%) coded for CTX-M group 1 ESBLs (CTX-M-1, 10 strains; CTX-M-15, 14 strains), 7 (20.5%) for CTX-M group 9 (all CTX-M-14), and 2 (6%) for CTX-M group 2 (both CTX-M-2). All of the CTX-M group 2-positive isolates, 50% of the CTX-M group 1-positive E. coli isolates, and only 14.3% of the members of CTX-M group 9 harbored additional blaTEM-1.

Besides β-lactam resistance, susceptibility to other classes of antibiotics was also tested; 26 strains were found resistant to tetracycline (76.5%), 23 strains were resistant to trimethoprim-sulfamethoxazole (67.6%), 10 strains were resistant to ciprofloxacin (29.4%), and 9 were resistant to aminoglycosides (26.4%). Four strains (11.8%) showed resistance to β-lactam antibiotics only (Table 1).

To identify relationships between the ESBL-producing strains, serotyping was carried out. All 34 strains were serotyped, resulting in as many as 29 different serotypes (Table 1). Only three serotypes, O2:48, O15:H18, and O102:H6, were found twice, and one, O153:H6, was found three times. This is in contrast to results for northwestern Spain, for example, where a strong predominance of O25b:H4 expressing CTX-M-15 was observed (28).

Currently, no studies describing the prevalence and characteristics of ESBL-producing Enterobacteriaceae in healthy human carriers are available in Switzerland, but there are two studies from Switzerland presenting data about infection-associated human ESBL producers (22, 31). The prevalence (0.7%) in hospitalized patients determined in 2007 was lower than in our study, but the CTX-M type distribution was the same (22). Despite the strict policy of antibiotic prescription in Switzerland (12), the determined prevalence rate of ESBL producers is almost identical to rates in other countries (25, 26, 34, 36). The increasing predominance of CTX-M group 1 enzymes, as has recently been described in strains from healthy food-producing animals in Denmark, France, the Netherlands, Portugal, and Switzerland (1, 13, 14, 16, 24) and in humans in the Netherlands, Norway, and Sweden (11, 24, 37), is also confirmed by our study. However, SHV-12—first described in Switzerland in 1997 (31)—has persisted in this country to the present day. The type mostly found in Switzerland, CTX-M-15, is distributed worldwide (4, 34). In contrast, CTX-M-9 together with CTX-M-14 (18, 28, 29), CTX-M-1 (4) and CTX-M-2 are the predominant types in Spain, Italy, and South America/Japan/Israel (2, 3, 4, 18, 29).

The fact that ESBL-producing strains are often also resistant to other classes of antimicrobial agents has been described in the past, and it is known that plasmids with blaCTX-M genes often carry genes conferring resistance to, e.g., quinolones, aminoglycosides, and co-trimoxazole, etc. (14, 15). This location of different resistance genes on single plasmid replicons could explain the successful dissemination of blaCTX-M genes by coselection (5, 15).

By serotyping, a high diversity within our ESBL producers was found (Table 1). The relatively high rates of intestinal carriage of ESBL producers in the general healthy human public and the high diversity among these strains, which is an indicator for high transmissibility of resistance factors, are worrisome. Further studies are necessary to assess future trends.

ACKNOWLEDGMENT

We thank the Swiss Federal Office of Public Health for partly funding the project.

FOOTNOTES

    • Received 15 August 2011.
    • Returned for modification 7 November 2011.
    • Accepted 6 December 2011.
    • Accepted manuscript posted online 12 December 2011.
  • Copyright © 2012, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Aarestrup FM,
    2. et al
    . 2006. First description of blaCTX-M-1-carrying Escherichia coli isolates in Danish primary food production. J. Antimicrob. Chemother. 57:1258–1259.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Ben-Ami R,
    2. et al
    . 2006. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin. Infect. Dis. 42:925–934.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bonnet R
    . 2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1–14.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Brigante G,
    2. et al
    . 2005. Evolution of CTX-M-type β-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int. J. Antimicrob. Agents 25:157–162.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Cantòn R,
    2. Coque TM
    . 2006. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol. 9:466–475.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Clinical Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100–S18. CLSI, Wayne, PA.
  7. 7.↵
    1. Cortés P,
    2. et al
    . 2010. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl. Environ. Microbiol. 76:2799–2805.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Duan RS,
    2. et al
    . 2006. Escherichia coli producing CTX-M β-lactamases in food animals in Hong Kong. Microb. Drug Resist. 12:145–148.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Eckert C,
    2. et al
    . 2004. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob. Agents Chemother. 48:1249–1255.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Eisner A,
    2. et al
    . 2006. Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum β-lactamase in Austria. Antimicrob. Agents Chemother. 50:785–787.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Fang H,
    2. Ataker F,
    3. Hedin G,
    4. Dornbusch K
    . 2008. Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J. Clin. Microbiol. 46:707–712.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Filippini M,
    2. Masiero G,
    3. Moschetti K
    . 2006. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy 78:77–92.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Geser N,
    2. et al
    . 2011. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in swine and cattle at slaughter in Switzerland. J. Food Prot. 74:446–449.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Girlich D,
    2. et al
    . 2007. Extended-spectrum β-lactamase CTX-M-1 in Escherichia coli in healthy poultry in France. Appl. Environ. Microbiol. 73:4681–4685.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Gniadkowski M
    . 2001. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin. Microbiol. Infect. 7:597–608.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Gonçalves A,
    2. et al
    . 2010. Genetic characterization of extended-spectrum β-lactamases in Escherichia coli isolates of pigs from a Portuguese intensive swine farm. Foodborne Pathog. Dis. 7:1569–1573.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Hammad AM,
    2. Ahmed AM,
    3. Ishida Y,
    4. Shimamoto T
    . 2008. First characterization and emergence of SHV-60 in raw milk of a healthy cow in Japan. J. Vet. Med. Sci. 70:1269–1272.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hernandez JR,
    2. Martinez-Martinez L,
    3. Cantón R,
    4. Coque TM,
    5. Pascual A
    . 2005. Spanish group for nosocomial infections (GEIH): nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob. Agents Chemother. 49:2122–2125.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Jensen LB,
    2. Hasman H,
    3. Agersø Y,
    4. Emborg HD,
    5. Aarestrup FM
    . 2006. First description of an oxyimino-cephalosporin-resistant, ESBL-carrying Escherichia coli isolated from meat sold in Denmark. J. Antimicrob. Chemother. 57:793–794.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Jouini A,
    2. et al
    . 2007. Characterization of CTX-M and SHV extended-spectrum β-lactamases and associated resistance genes in Escherichia coli strains of food samples in Tunisia. J. Antimicrob. Chemother. 60:1137–1141.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Kolár M,
    2. et al
    . 2010. Prevalence of ESBL-positive Enterobacteriaceae in large Moravian hospitals (Czech Republic). Klin. Mikrobiol. Infekc. Lek. 16:152–157. (In Czech.)
    OpenUrlPubMed
  22. 22.↵
    1. Lartigue MF,
    2. et al
    . 2007. Extended-spectrum β-lactamases of the CTX-M type now in Switzerland. Antimicrob. Agents Chemother. 51:2855–2860.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Lartigue MF,
    2. Fortineau N,
    3. Nordmann P
    . 2005. Spread of novel expanded-spectrum β-lactamases in Enterobacteriaceae in a university hospital in the Paris area, France. Clin. Microbiol. Infect. 11:588–591.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Leverstein-van Hall MA,
    2. et al
    . 2011. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin. Microbiol. Infect. doi:10.1111/j.1469-0691.2011.03497.x.
  25. 25.↵
    1. Luvsansharav UO,
    2. et al
    . 2011. Prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J. Infect. Chemother. doi:10.1007/s10156-011-0225-2.
  26. 26.↵
    1. Mesa RJ,
    2. et al
    . 2006. Extended-spectrum β-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). Antimicrob. Chemother. 58:211–215.
    OpenUrlCrossRef
  27. 27.↵
    1. Meunier D,
    2. Jouy E,
    3. Lazizzera C,
    4. Kobisc M,
    5. Madec JY
    . 2006. CTX-M-1- and CTX-M-15-type β-lactamases in clinical Escherichia coli isolates recovered from food-producing animals in France. Int. J. Antimicrob. Agents 28:402–407.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Mora A,
    2. et al
    . 2011. Emergence of clonal groups O1:HNM-D-ST59, O15:H1-D-ST393, O20:H34/HNM-D-ST354, O25b:H4-B2-ST131 and ONT:H21,42-B1-ST101 among CTX-M-14-producing Escherichia coli clinical isolates in Galicia, northwest Spain. Int. J. Antimicrob. Agents. 37:16–21.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Novais A,
    2. et al
    . 2006. Dissemination and persistence of blaCTX-M-9 are linked to class 1 integrons containing CR1 associated with defective transposon derivatives from Tn402 located in early antibiotic resistance plasmids of IncHI2, IncP1-α, and IncFI groups. Antimicrob. Agents Chemother. 50:2741–2750.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Nüesch-Inderbinen MT,
    2. Hächler H,
    3. Kayser FH
    . 1996. Detection of genes coding for extended-spectrum SHV β-lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur. J. Clin. Microbiol. Infect. Dis. 15:398–402.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Nüesch-Inderbinen MT,
    2. Kayser FH,
    3. Hächler H
    . 1997. Survey and molecular genetics of SHV β-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob. Agents Chemother. 41:943–949.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Ørskov K,
    2. Ørskov I
    . 1984. Serotyping of Escherichia coli. Methods Microbiol. 14:43–122.
    OpenUrlCrossRefWeb of Science
  33. 33.↵
    1. Pitout JD,
    2. et al
    . 1998. β-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob. Agents Chemother. 42:1350–1354.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Tängdén T,
    2. Cars O,
    3. Melhus A,
    4. Löwdin E
    . 2010. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum β-lactamases: a prospective study with Swedish volunteers. Antimicrob. Agents Chemother. 54:3564–3568.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Tian GB,
    2. et al
    . 2009. Detection of CTX-M-15, CTX-M-22, and SHV-2 extended-spectrum β-lactamases (ESBLs) in Escherichia coli fecal-sample isolates from pig farms in China. Foodborne Pathog. Dis. 6:297–304.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Tian SF,
    2. Chen BY,
    3. Chu YZ,
    4. Wang S
    . 2008. Prevalence of rectal carriage of extended-spectrum β-lactamase-producing Escherichia coli among elderly people in community settings in China. Can. J. Microbiol. 54:781–785.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Tofteland S,
    2. et al
    . 2007. Effects of phenotype and genotype on methods for detection of extended-spectrum β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J. Clin. Microbiol. 45:199–205.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Woodford N,
    2. Fagan EJ,
    3. Ellington MJ
    . 2006. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β-lactamases. J. Antimicrob. Chemother. 57:154–155.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Molecular Identification of Extended-Spectrum-β-Lactamase Genes from Enterobacteriaceae Isolated from Healthy Human Carriers in Switzerland
Nadine Geser, Roger Stephan, Bozena M. Korczak, Lothar Beutin, Herbert Hächler
Antimicrobial Agents and Chemotherapy Feb 2012, 56 (3) 1609-1612; DOI: 10.1128/AAC.05539-11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Identification of Extended-Spectrum-β-Lactamase Genes from Enterobacteriaceae Isolated from Healthy Human Carriers in Switzerland
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
Molecular Identification of Extended-Spectrum-β-Lactamase Genes from Enterobacteriaceae Isolated from Healthy Human Carriers in Switzerland
Nadine Geser, Roger Stephan, Bozena M. Korczak, Lothar Beutin, Herbert Hächler
Antimicrobial Agents and Chemotherapy Feb 2012, 56 (3) 1609-1612; DOI: 10.1128/AAC.05539-11
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596